Trial Profile
Breeze 3: Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Hot flashes; Menopausal syndrome
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-3
- Sponsors Assertio Therapeutics; Depomed
- 12 Oct 2013 Pooled analysis of the BREEZE-1, -2 and -3 trials presented at the 24th Annual Meeting of the North American Menopause Society.
- 06 Oct 2012 Primary efficacy results presented at the 23rd Annual Meeting of the North American Menopause Society.
- 06 Oct 2012 Results assessing the effects of treatment on sleep parameters presented at the 23rd Annual Meeting of the North American Menopause Society.